1 Langham Resource, Bioscience Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545; and 2 Institute of Pathology, University of Regensburg, 93042 Regensburg, Germany
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Rat1-T1 and MR1 spheroids represent separate transformed phenotypes originated from the same rat fibroblasts that differ in three-dimensional (3D) growth kinetics, histological structure, and oxygenation status. In the present study, 31P-NMR spectroscopy of perfused spheroid suspensions was used to investigate cellular energetics relative to 3D growth, development of necrosis, and cell cycle distribution. Both spheroid types were characterized by a remarkably low amount of free (inorganic) phosphate (Pi) and a low phosphocreatine peak. The ratio of nucleoside triphosphate (NTP) to Pi ranged between 1.5 and 2.0. Intracellular pH, NTP-to-Pi ratio, and NTP/cell remained constant throughout spheroid growth, being unaffected by the emergence of oxygen deficiency, cell quiescence, and necrosis. However, a 50% decrease in the ratio of the lipid precursors phosphorylcholine and phosphorylethanolamine (PC/PE) was observed with increasing spheroid size and was correlated with an increased G1/G0 phase cell fraction. In addition, the ratio of the phospholipid degradation products glycerophosphorylcholine and glycerophosphorylethanolamine (GPC/GPE) increased with spheroid diameter in Rat1-T1 aggregates. We conclude that changes in phospholipid metabolism, rather than alterations in energy-rich phosphates, reflect cell quiescence in spheroid cultures, because cells in the inner oxygen-deficient zones seem to adapt their energy metabolism to the environmental conditions before necrotic cell destruction.
energy metabolism; tumor biology; nuclear magnetic resonance spectroscopy; phospholipids; quiescence
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
MAGNETIC RESONANCE SPECTROSCOPY (MRS) is increasingly utilized as an in vivo method to monitor cell metabolism and tissue oxygenation in various organs and diseases (17, 27, 41, 49). New approaches include its application in neuropsychiatric and toxicology research (5, 10, 46, 61), and it is widely applied in pharmacokinetic and comparative physiological studies (47, 50, 56, 67, 84). MRS has also become a powerful technological tool providing noninvasive access to tumor bioenergetic state because of its most attractive feature of nondestructively measuring chemical compounds in intact, living tissues (17, 27). Combinations of advanced MRS techniques with labeled compounds and genetic manipulation are now allowing in situ measurements of specific metabolic pathways in tumors (8, 58, 67, 71, 87).
Experimental, preclinical, and clinical spectroscopy results indicate that cancers have typical metabolic characteristics that might be of diagnostic and/or prognostic relevance and could be used to some extent as predictors of cancer treatment outcome (17, 24, 31, 42, 45, 51, 54, 57, 64, 70). Among other things, measurement of tumor energetics by 31P-NMR spectroscopy provides useful information about tumor oxygenation/hypoxia and potential therapeutic resistance. However, there is some controversy about the relevance of the additional parameters that can be monitored in tumors via phosphorous NMR, e.g., phospholipid metabolism (15, 16, 26, 43, 44, 62, 68, 79). It was previously reported that most human tumors contain high concentrations of phosphomonoesters, with the major compounds being identified as phosphorylethanolamine (PE) and phosphorylcholine (PC) (15, 54, 72). Yet most of these studies raise an important question: Are modifications in the phospholipid metabolism of tumor cells due to an increase in proliferative activity rather than to tumorigenic conversion?
Over the past decade much work has also concentrated on establishing correlations between 31P-NMR data and physiological or environmental factors to analyze more precisely cellular mechanisms influencing the NMR spectra. Parameters of energy status that have been used in 31P-spectroscopy are typically the ratio of nucleotide triphosphate (NTP) and phosphocreatine (PCr) to inorganic phosphate (Pi) and related ratios as well as the intracellular pH (pHi). Although changes in these parameters have been correlated with necrosis and tumor oxygen status in some particular tumors, no correlation was found in others (17, 24, 25, 27, 42, 48, 58, 59, 60, 74, 85).
The interpretation of in vivo tumor NMR data to address basic metabolic questions is hampered by several factors, e.g., tissue/tumor heterogeneity, in particular tumor vascularization and nutrient supply, and lack of experimental control over environmental conditions (34, 48, 73). Multicellular spheroids represent a well-established in vitro model for investigation of the interrelationship among growth/proliferation kinetics, viability, and energetic state of tumor cells (23, 39, 53). An NMR system for viably maintaining a stirred suspension of multicellular spheroids during NMR spectroscopy has been established in our laboratory (20). Based on this technical development, a few 31P-NMR studies have focused on the phenomenon of the development of a quiescent cell population in the inner viable cell rim of spheroids and the emergence of necrosis. For EMT6/Ro mouse mammary carcinoma spheroids, a negative correlation between the ratio of the membrane phospholipid precursors PE and PC and the S phase cell fraction was documented whereas pHi and the ratios of NTP to Pi and PCr to Pi did not significantly change as a function of spheroid size, proliferative activity, and/or extent of central necrosis (21).
To investigate in more detail the relationship among proliferation, oxygen supply, cell viability, and cellular energetics we have studied two established and well-characterized oncogene-transfected rat embryo fibroblast spheroid types using 31P-MRS. Although these two cell lines are genetically closely related, thus representing to some extent cellular heterogeneity in a rat tumor, they clearly differ in three-dimensional (3D) culture in the following characteristics: 1) growth kinetics, proliferative activity and cell viability; 2) cell shape and histological structure involving the development of necrosis; 3) oxygen consumption and distribution, 4) mitochondrial activity, and 5) ATP, glucose, and lactate concentrations as measured by various bioluminescence techniques (35-38, 40). In the present study, we report 31P-NMR spectroscopic data on these two spheroid types as a function of spheroid size, cell cycle distribution, and the development of necrosis.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell lines and spheroid culturing. The highly tumorigenic cell clones Rat1-T1 and MR1 were derived from two different immortalized rat fibroblast cell lines by T24Ha-ras transfection. The parental cell lines (Rat1 and M1) were originated from Fisher 344 rat embryo fibroblasts (REFs) either spontaneously or via transfection with c-myc1, which was isolated from a mouse plasmacytoma. Ras transfection was carried out with the oncogene plasmid pHO6T1, which contains a single-base mutant 6.6-kb c-Ha-ras gene isolated from a human bladder carcinoma. Cell lines, oncogenes, and the transfection protocol have been detailed in previous publications (35, 36, 40).
Monolayer stock cultures were routinely subcultured and periodically tested for mycoplasmal contamination via standardized techniques as described previously (36). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO, Gaithersburg, MD) with the addition of D-glucose to a final concentration of 4.5 g/l (Sigma, St. Louis, MO), 5% (vol/vol) fetal calf serum (Sigma), 100 IU/ml potassium penicillin, and 100 µg/ml streptomycin sulfate (GIBCO). Spheroids were initiated and cultured essentially as documented previously (37). Spheroid growth was initiated either in microbiological petri dishes or 0.5% (wt/vol) agar-coated culture dishes (1-2 × 105 cells per 100-mm dish), and spheroids were maintained in spinner flasks with continuous stirring after an initiation interval of 4 days. Complete DMEM as described above was used for spheroid culturing. Medium was replenished daily, and the number of spheroids was continuously reduced to keep the cell count in the spinner flask relatively constant, ensuring an essentially constant medium condition throughout growth. Monolayer and spheroid cultures were kept in a humidified atmosphere with 5% (vol/vol) CO2 in air at 37°.Spheroid volume and histology. The mean (±SD) spheroid volume within hand-selected spheroid populations was calculated from 50 individual spheroid diameter values. For each spheroid observed, minor and major diameters were measured and averaged with a calibrated image processing apparatus consisting of an inverted microscope (Stemi SVII; Zeiss) connected to a solid-state camera (COHU Electronics) with monitor and a Macintosh-based computer system for image analysis (NIH Image).
For histological observation (e.g., thickness of the viable cell rim), spheroids were fixed in 2.5% (vol/vol) glutaraldehyde or 10% buffered formalin, mounted in paraffin, serially sectioned into 5-µm-thick slices, and stained with hematoxylin and eosin. Central sections were detected taking into account an average shrinkage of 18% due to histological processing. Measurements of the thickness of the viable cell rim in central sections were done with a calibrated reticule in a microscope as detailed previously (23).Cell counting, volume, and cell cycle distribution.
Cells dissociated from spheroids by mild trypsinization
(0.125-0.25% trypsin) and mechanical means were counted with a
standard particle counter (Coulter, Hialeah, FL) equipped with a pulse height analyzer (Nucleus). Acellular debris was excluded from the cell
count by determining a region of interest for the cell volume as
described previously (20). Cell volume distributions of
10,000 cells per cell population were used to calculate the average
cellular volume based on calibration of the system with polystyrene microspheres.
31P-NMR measurements.
For NMR experiments, hand-selected groups of spheroids were transferred
into a specially designed perfusion chamber connected to a perfusion
system as documented previously (21). We have devised a
novel type and size of perfusion chamber for maintaining a viable
suspension of multicellular spheroids during NMR spectroscopy, which
increased the temporal resolution by a factor of 10 compared with
previous studies (Fig. 1A). By
using completely relaxed acquisition conditions, a 1-h spectrum with a
signal-to-noise ratio of 10 could be collected using only
2-3 × 107 cells. Other advantages of the new
type of chamber include the integrated containers for standard solution
that can be easily filled from the outside and the fact that the cell
suspension is mixed by the perfusion flow, avoiding the use of a
stirring device controlled by an external motor.
|
31P-NMR analysis. Phosphorous NMR spectra were recorded at 161.97 MHz with a Bruker AM400wb spectrometer system (9.7 T). A 10,000-Hz (61.74 ppm) sweep was accumulated in 4,096 data points in an acquisition time of 0.27 s with a recycle time of 10 s after a 90° (15 µs) pulse. Spectra were stored every 360 scans (60 min 47 s), and 5-20 spectra were added for subsequent peak analysis. Chemical shifts were recorded with respect to 85% H3PO4 and were analyzed by setting the resonance of the external methylenediphosphonic acid (MDA) standard to 16.8 ppm. Peak height analysis was carried out with Bruker analysis software (Bruker Instruments, Billerica, MA). Peak heights in a spectrum within a given experiment were referenced to the corresponding height of the MDA peak (25 mM; 16.4 µl) in the spectrum (20, 21).
Statistical analysis. Pairwise comparisons were performed with a two-tailed Student's t-test based on the means and standard deviations of three to five repeated measurements, with differences considered statistically significant when P < 0.05. Correlations between two parameters were determined by least-squares best fits to a linear equation, and the parameters were considered significantly correlated when r > 0.5.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
It was documented previously that spheroid volume growth and
histology of the two oncogene-transfected fibroblast cell lines differ,
with MR1 aggregates reaching maximum volumes at days 12-14 and
Rat1-T1 spheroids entering spheroid plateau phase approximately at days
20-24 after an initiation interval of 4 days in petri dishes or
agar-coated culture dishes (36). This growth behavior has
been confirmed in the present study (Fig.
2A), and cell cycle distributions have been determined via flow cytometry in parallel (Fig.
2, B-D). Spheroid volume growth was mathematically
described by the Gompertz equation as detailed previously
(36). The corresponding fits are shown as lines in Fig.
2A. For cell cycle distributions we could show that the
number of cells in G1/G0 significantly increased as a function of the spheroid size (P < 0.01) and the number of cells in S phase was continuously reduced, with
minimum values of 10-15% of the total. At the same time, the
proportion of cells in G2/M phase significantly decreased
in Rat1-T1 but not MR1 spheroids, suggesting a G2/M phase
block in these cells as well. In general, cell growth kinetics were
reflected by the cell cycle distributions, with 1) a lower
proportion of cells in S phase within the slower-growing Rat1-T1 as
opposed to MR1 spheroids and 2) a clear reduction in
the S phase cell fraction and an increase in the percentage of
cells in G1/G0 phase accompanying spheroid
volume growth retardation in both spheroid types.
|
Cell count per spheroid, cell volume, and thickness of the viable cell rim recorded in the present study correspond with data published previously (36). Within the spheroid size range investigated via NMR spectroscopy, the cell number per spheroid exponentially increased for both spheroid types and the average cell volume remained relatively constant. The mean thickness of viable cell rim was 202 ± 26 µm in Rat1-T1 (n = 26), which is in accordance with values reported previously (36), whereas the viable cell rim of MR1 spheroids was slightly smaller than described previously, measuring some 279 µm with a standard deviation of 44 µm (n = 37). This value reflects the high variance in the thickness of viable cell layers within this spheroid type, probably due to its loose cell packing density associated with a high rate of cell shedding on the spheroid surface. Although Groebe and Mueller-Klieser (29) showed that necrosis expands quickly after initial induction, over the spheroid size range investigated in this study there was no significant change in the thickness of the viable cell rim with increasing spheroid diameter, as has been reported for other cell lines (23).
Because the energetic parameters analyzed via 31P-NMR
spectroscopy were constant over an experimental period of >15 h in the new type of perfusion chamber, we have added at least four 1-h spectra
for subsequent further analysis. Figure 3
shows representative added 31P-NMR spectra of small and
large Rat1-T1 and MR1 spheroids. Figure 4
summarizes the results on the cell energetic parameters
pHi, -NTP/Pi, and
-NTP per cell
quantified from the added NMR spectra. It could be shown that neither
pHi nor the
-NTP-to-Pi ratio significantly changed throughout spheroid growth (r < 0.1). Also,
the development of a histologically detectable central necrotic region
at spheroid sizes of 500-600 µm for Rat1-T1 and 800-900
µm for MR1 aggregates was not accompanied by systematic changes in
pHi and
-NTP/Pi. However, cell line-specific
differences of the two tumorigenic fibroblast spheroid types are not
only manifested in spheroid proliferation, structure, and oxygenation
but could also be identified in the NMR spectra. As a result, MR1
spheroids were characterized not only by a higher proliferative
activity and a higher S phase cell fraction during spheroid volume
growth but also by a 1.5-times lower overall
-NTP-to-Pi
ratio compared with Rat1-T1 spheroids. In addition, a slight but
significant (r = 0.91) decline in the
-NTP
concentration/cell as a function of spheroid diameter was observed for
Rat1-T1 but not MR1 spheroids. Because the cell volume in both MR1 and
Rat1-T1 spheroids did not consistently change as a function of spheroid
size, the negative correlation between
-NTP per Rat1-T1 cell and
spheroid diameter was not due to cell volume alterations.
|
|
Analysis of phosphomonoesters and phosphodiesters from the NMR spectra
showed that the PC-to-PE ratio systematically decreased with
spheroid diameter, which might be associated with cell quiescence (Fig. 5C). As documented in
Fig. 5, A and B, the modifications in PC/PE were
due to a significant reduction in PC with spheroid growth
(r > 0.53) while the PE level per cell was constant
throughout spheroid growth (r < 0.1). In addition, MR1
spheroids that were characterized by a shorter spheroid volume doubling
time and a higher proportion of S phase cells accompanied by a lower
G1/G0 phase cell fraction exhibited higher
PC/PE compared with Rat1-T1 aggregates of the same size category.
Because the decline in PC was not significantly different in Rat1-T1
and MR1 spheroids as a function of spheroid diameter (P > 0.05 comparing the slopes), differences in PC/PE between the two
cell lines seem to relate to the increased amount of PE in the Rat1-T1
spheroids.
|
In contrast to the phospholipid precursor PC, no significant
correlation of the single-phospholipid degradation products GPC and GPE
and spheroid size was found (r < 0.05, Fig.
6, A and B), although the calculated ratio GPC/GPE was positively correlated with
the aggregate size of Rat1-T1 cultures (P < 0.05) as
shown in Fig. 6C. The increase in GPC/GPE throughout Rat1-T1
spheroid growth mirrors the changes in the phospholipid precursor ratio PC/PE. A similar correlation was not shown for MR1 cells in spheroids because the GPE peak was not consistently detectable in the added spectra (see, e.g., Fig. 3) and peak height analysis could not be
performed.
|
The observations of this study can be summarized as follows. First,
both fibroblast spheroid types were characterized by an extremely low
PCr peak, which could be observed in the added but not the single 1-h
spectra. Second, Pi was only moderate relative to -NTP;
thus
-NTP/Pi was clearly >1 for both spheroid types and
did not significantly change throughout spheroid growth, similar to pHi. Third, focusing on the phosphomonoesters, the
same characteristics were found in Rat1-T1 and MR1 spheroids, with a
constant cellular PE level and a decrease in PC concentration per cell
throughout growth resulting in a reduction of PC/PE as a function of
spheroid size. Fourth, a slight increase in the phosphodiester GPC per cell could be recorded for both spheroid types whereas the cellular concentration of the phospholipid degradation product GPE was a
constant function of spheroid size (Rat1-T1 spheroids) and GPC/GPE clearly increased throughout growth of Rat1-T1 spheroids.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Over the past 10 years, fibroblasts transformed to differing extents have gained experimental importance, leading to a deeper insight into mechanisms underlying the multistep process of transformation. Recently, four differently transformed rat fibroblast cell lines have been well characterized in multicellular spheroid culture (35, 36, 40). Among other things, it could be demonstrated that even fibroblast clones that were originated from the same stem cells and belonged to a similar transformation stage such as Rat1 and M1 cells or Rat1-T1 and MR1 cells showed a variety of pathophysiological differences in two-dimensional (2D) and, in particular, 3D culture. The two diploid cell lines used for the present investigation (Rat1-T1 and MR1) represent tumorigenic, fully transformed phenotypes within an oncogene-dependent two-step transformation model that differ only in the immortalization process. As documented previously, differences of Rat1-T1 and MR1 spheroids in vitro that might represent in vivo heterogeneity of tumor physiology and microenvironment include the following: 1) development of necrosis, 2) thickness of viable cell rim, 3) proliferative activity, and 4) oxygen gradient (35, 36).
We have carried out phosphorous magnetic resonance measurements of perfused suspensions of spheroids to verify whether the differences in oxygen availability, cell viability, and proliferative activity in Rat1-T1 and MR1 spheroids are reflected by any of the steady-state energetic parameters that can be determined from 31P-NMR spectra. Investigations on the energy metabolism of these morphologically well-defined spheroid types provide useful information on tumor cell biology because changes in tumor energetics such as ATP level and pH have been positively correlated with oxygen supply, glucose distribution, and/or necrosis in some tumors in vivo and in some but not all experimental systems in vitro (17, 24, 25, 27, 42, 48, 58-60, 74, 85). One interpretation of some controversial data in the literature has been discussed by Steen (74), who suggested different types of hypoxia, with metabolic hypoxia resulting in mitochondrial impairment in cells associated with a drop in ATP and a radiobiological-type hypoxia resulting in attenuated cell death related to radiation-sensitive tissue levels of oxygen. As a result, metabolic hypoxia could be detected in the 31P-NMR spectra, whereas the radiobiological hypoxia would be invisible. Previous work with spheroids does not support this hypothesis (20, 21). However, in the spheroid types investigated previously, metabolic hypoxia was accompanied by necrotic cell death, which probably contributes nothing to the 31P spectrum (27, 81). With the MR1 spheroid type, which contains a 10-15% fraction of viable cells under metabolically hypoxic conditions, we have an excellent model to verify whether metabolic hypoxia is reflected by changes in the NTP resonances. In addition, MR1 and Rat1-T1 spheroids are characterized by a decrease in mitochondrial activity both as a function of location in the spheroid and throughout growth (37-39), as has been reported for other cell lines (18, 19).
As opposed to phosphorous spectra determined for EMT6 (mouse mammary carcinoma) and 9L (rat gliosarcoma) spheroids, both tumorigenic fibroblast aggregate types were characterized by a remarkably low amount of free phosphate (Pi) whereas no PCr could be observed. Consequently, the ratio of NTP to Pi ranged between 1.5 and 2.0 in Rat1-T1 and MR1 spheroids compared with a value of ~1.0 for EMT6 and 9L spheroids (20, 21), suggesting large differences in the metabolic turnover rates of tumorigenic rat fibroblasts and these other tumor cells in 3D culture. However, for all spheroid types tested so far, including Rat1-T1 and MR1, the NTP-to-Pi ratio and pHi remained constant as a function of the spheroid diameter. A significant decline in the NTP per cell throughout growth was shown only for Rat1-T1 spheroids and was confirmed by bioluminescence measurements of the ATP concentration (µmol/g) in the viable cell rim of this spheroid type (38). However, this decrease was positively correlated with reduction in cell volume and NTP/cell volume was constant.
The lack of correlation between pHi or NTP/Pi and the development of necrosis and cell quiescence in both fibroblast spheroid types implies that tumor cells in the inner, nutrient-deficient spheroid areas adapted their energy metabolism to the changing microenvironment. Similar results obtained for other spheroid types indicate that the maintenance of a constant ratio of high-energy phosphates to Pi via cellular metabolic adaptation might be a general aspect of viable cells within 3D culture (21). It must be pointed out that the majority of MR1 spheroids with a diameter >1,000 µm consisted of an inner 50- to 75-µm-thick region of viable but cell cycle-arrested cells in which no oxygen could be detected with oxygen-sensitive microelectrodes. This zone corresponds to ~15% of the total spheroid cells, so that a large decrease in energy metabolism in this subpopulation of cells should have been detected as a decrease in the averaged values reported in this study. Even in this spheroid type, NTP/Pi was constant as a function of spheroid size and occurrence of the oxygen-deficient viable cell zone was not reflected by a drop in NTP/Pi. We conclude that quiescent MR1 cells are highly resistant to lack of oxygen as opposed to other cell types such as Rat1-T1, EMT6, or 9L cells in 3D culture (21, 36) and that they may compensate for the resulting energy loss by utilizing additional, nonaerobic energetic sources such as glucose or glutamine. Preliminary experiments on glucose consumption per spheroid volume unit indicate that glucose is not the major factor involved in anaerobic energy compensation, because 1) there is no significant difference in glucose uptake of Rat1-T1 and MR1 spheroids and 2) glucose uptake decreases as a function of spheroid diameter (unpublished data), as has been shown for other cell types (22). Bourrat-Floeck and coworkers (9) described the phenomenon of lactate utilization in large EMT6 spheroids, whereas small spheroids produced large amounts of lactate as expected. It may be speculated from their observation that a similar mechanism is activated in quiescent, oxygen-deficient MR1 cells. Determination of lactate and glucose levels and uptake/release rates in the two spheroid types with an advanced bioluminescence technique and routine enzymatic tests is in progress (86). The contribution of glutathione (GSH) in the regulation of energy metabolism as an antioxidant agent may also be considered, because Romero et al. (64) showed that GSH concentration per cell may change throughout spheroid growth, with a sharp increase around the diameter where necrosis occurs in V79 hamster lung cell spheroids. In summary, our data support previously reported work with spheroids and imply that cellular metabolic adaptation in the inner spheroid regions might be a general phenomenon in 3D cultures despite a changing microenvironment, nutrient deficiency, and loss in mitochondrial activity. The fact that mitochondrial activity does not affect NTP/Pi in the cells seems peculiar. However, Rasmussen et al. (63) showed that azide, an inhibitor of mitochondrial respiration, had no effect on the ATP concentration if adequate levels of glucose were present. Investigations by Teutsch et al. (78) using a modified Lowry technique for glucose detection indicate that sufficient glucose is available even in the center of large spheroid cultures.
Phospholipid metabolites have been discussed as indicators of cancer cell function, with two main kinds of phospholipid-related peaks that appear in the phosphorous spectrum: 1) phosphomonoesters PC and PE synthesized by the enzymatic activity of specific kinases that catalyze the first step of phospholipid biosynthesis in vivo and 2) phosphodiesters GPC and GPE, the two major phospholipid breakdown products (68, 83). Data in the literature indicate that the relationship between tumor growth and progression, respectively, and single components in the phospholipid metabolism seems to be ambiguous (4, 7, 43, 44, 52, 55, 71). However, numerous recent studies have demonstrated a correlation between mitogenic stimulation and/or oncogenic transformation of cells and acute changes in phospholipid pathways such as transient increases in concentrations of certain metabolites and an increase in lipid turnover rate (1-3, 11, 13, 28, 33, 66, 82). In most cases, enhanced phospholipid biosynthesis and reduced phospholipid breakdown were observed in long-term chronic situations such as tumors and high phosphomonoester (PME) levels have been hypothesized to be the best biochemical marker to distinguish some cancerous from normal tissues (16, 17, 43, 52, 55, 62, 65) and to monitor tumor treatment outcome (69, 75). Some but not all of these observations might be due to the fact that under certain conditions PC strongly correlates with cell proliferation (4, 6, 21, 26, 62, 68, 72, 82). Ting et al. (80) compared the metabolism of different human breast cancer cells and normal mammary epithelial cells with a similar proliferative activity. They showed that, in contrast to high-energy phosphates and aerobic glycolysis, which did not reveal distinct differences between normal and cancer cells, levels of PC and PE were significantly higher in the tumor cells. In accordance with this finding, Cox et al. (12) demonstrated that liver tumors are characterized by an increase in PE and PC signals and a decrease in GPC and GPE signals, with the spectral changes being independent on tumor type, i.e., hepatocellular carcinoma, secondary adenocarcinoma, or squamous cell carcinoma. The higher levels of PE and PC in tumor extracts in vitro compared with normal tissue correlated with an increased PME peak seen in vivo. Lyng et al. (44) demonstrated that PME and PDE in 31P-NMR spectra in different human melanoma xenografts in vivo did not correlate with the rate of tumor cell proliferation and S phase cell fraction. In addition, Abraha et al. (1) and Street and Koutcher (75) could not confirm a significant effect of different therapeutic modalities on phospholipid precursors and catabolites in either perfused RIF-1 fibrosarcoma cells or extracts of a murine breast carcinoma cell system. They concluded that phospholipid precursors and breakdown products are of limited value in prediction of tumor treatment outcome as suggested by others who found specific changes in particular in the phosphomonoester resonances associated with reduced cell viability and proliferation after radio- or chemotherapy (16, 42, 45, 51, 68, 74). Despite contradictory results with phospholipid measurements, increased total choline levels in tumors are being investigated as a means of detecting prostate cancer with 18F-labeled choline and positron emission spectroscopy (14).
In contrast to the lack of relation between the NTP signal and cell
quiescence and necrosis, respectively, a clear negative correlation
between PC/PE and the spheroid diameter could be shown with the faster
growing/proliferating spheroid type MR1 characterized by a higher
overall PC/PE. Analysis of the single parameters PC and PE per cell
revealed that the alteration is solely due to a decrease in the PC peak
whereas PE/cell remains constant throughout spheroid growth. Figure
7 documents the correlation between PC/PE and the proportion of cells in G1/G0 phase,
which can be estimated from Fig. 2C. Linear regression
analysis of PC/PE vs. G1/G0 phase cell fraction
indicates that the correlation might be cell line independent for the
fibroblast cell system tested. It must be kept in mind that the
absolute amounts of PC and PE could vary between different cell lines,
as is clearly shown for PE (Fig. 5B). Thus, although the
absolute value of PC/PE may not correlate with proliferation when
comparing different cell lines, our results support the hypothesis of a
general correlation between lipid (precursor) metabolism and
proliferative status. However, from the analysis of our data we assume
that the accumulation of cells in G1/G0 and
probably the occurrence of G0 phase cells itself are
reflected by a change in phospholipid metabolism rather than the
decrease of actively cycling cells. Because it was proposed several
years ago that an increased PC level might be a marker of cell
differentiation (1, 2, 28), future investigations will
have to determine whether the accumulation of G0 phase
cells in tumors is similar to cell differentiation in normal tissue in
terms of phospholipid metabolism.
|
It was also hypothesized in the early 1980s that an increase in the phospholipid breakdown products GPE and GPC may be a indicator of the necrotic fraction in tumors as a consequence of membrane degradation (27). However, Smith et al. (72, 73) cited some breast tumors that contained appreciable levels of GPE and GPC without gross necrosis. 3D cultures such as spheroids exhibiting central necrosis at a specific size range are an excellent model system to verify whether necrotic cell death is associated with accumulation of GPE and/or GPC. Although the 31P-NMR spectra of MR1 spheroids did not allow for quantitation of the GPE peak, the following observations could be made: 1) neither GPE nor GPC changed drastically as a function of the spheroid size in both spheroid types investigated, and 2) development of necrosis was not accompanied by quantitative alterations in the phospholipid breakdown products. In earlier studies using mouse and rat tumor cells, Freyer et al. (21) found no correlation between GPC or GPE levels, spheroid growth, or the development of necrosis. A detailed understanding of the changes observed in phospholipid precursor and degradation products will require more sophisticated NMR approaches such as 13C-labeled precursors (32, 66) or NMR-visible analogs (76, 77).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Nicole Ballew for excellent technical assistance.
![]() |
FOOTNOTES |
---|
This work was supported by DFG grants Ku 917/1-1 and Ku 917/1-2 and National Cancer Institute Grant CA-51150.
Address for reprint requests and other correspondence: J. P. Freyer, Langham Resource, Bioscience Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545 (E-mail: freyer{at}lanl.gov).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpcell.00097.2002
Received 4 March 2002; accepted in final form 9 June 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Abraha, A,
Shim H,
Wehrle JP,
and
Glickson JD.
Inhibition of tumor cell proliferation by dexamethasone: 31P NMR studies of RIF-1 fibrosarcoma cells perfused in vitro.
NMR Biomed
9:
173-178,
1996[ISI][Medline].
2.
Ackerstaff, E,
Pflug BR,
Nelson JB,
and
Bhujwalla ZM.
Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.
Cancer Res
61:
3599-3603,
2001
3.
Agris, PF,
and
Campbell ID.
Proton nuclear magnetic resonance of intact Friend leukemia cells: phosphorylcholine increase during differentiation.
Science
216:
1325-1327,
1982[ISI][Medline].
4.
Aiken, NR,
and
Gillies RJ.
Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors.
Anticancer Res
16:
1393-1397,
1996[ISI][Medline].
5.
Arnold, DL,
and
De Stefano N.
Magnetic resonance spectroscopy in vivo: applications in neurological disorders.
Ital J Neurol Sci
18:
321-329,
1997[ISI][Medline].
6.
Barba, I,
Mann P,
Cabanas ME,
Arus C,
and
Gasparovic C.
Mobile lipid production after confluence and pH stress in perfused C6 cells.
NMR Biomed
14:
33-40,
2001[ISI][Medline].
7.
Bell, JD,
and
Bhakob KK.
Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours.
NMR Biomed
11:
354-359,
1998[ISI][Medline].
8.
Bhujwalla, ZM,
Aboagye EO,
Gillies RJ,
Chacko VP,
Mendola CE,
and
Backer JM.
Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro.
Magn Reson Med
41:
897-903,
1999[ISI][Medline].
9.
Bourrat-Floeck, B,
Groebe K,
and
Mueller-Klieser W.
Biological response of multicellular EMT6 spheroids to exogenous lactate.
Int J Cancer
47:
792-799,
1991[ISI][Medline].
10.
Brauer, M.
Magnetic resonance imaging and spectroscopy: new noninvasive in vivo approaches in toxicology research.
Altern Lab Anim
21:
411-425,
1993[ISI].
11.
Carpinelli, G,
Podo F,
Di Vito M,
Proietti E,
Gessani S,
and
Bellardelli F.
Modulation of glycerophosphorylcholine and phosphorylcholine in Friend erythroleukemia cells upon in vitro-induced erythroid differentiation: a 31P NMR study.
FEBS Lett
176:
88-92,
1984[ISI][Medline].
12.
Cox, IJ,
Bell JD,
Penden CJ,
Iles RA,
Foster CS,
Watanapa P,
and
Williamson RCN
In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies.
NMR Biomed
5:
114-120,
1992[ISI][Medline].
13.
Daly, DF,
Lyon RC,
Faustino PJ,
and
Cohen JS.
Phospholipid metabolism in cancer cells monitored by 31P-NMR spectroscopy.
J Biol Chem
262:
14875-14878,
1987
14.
DeGrado, TR,
Coleman RE,
Wang SY,
Baldwin SW,
Orr MD,
Robertson CN,
Polascik TJ,
and
Price DT.
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
Cancer Res
61:
110-117,
2001
15.
Dixon, RM.
NMR studies of phospholipid metabolism in hepatic lymphoma.
NMR Biomed
11:
370-379,
1998[ISI][Medline].
16.
Dueck, DA,
Chan M,
Tran K,
Wong JT,
Jay FT,
Littman C,
Stimpson R,
and
Choy PC.
The modulation of choline phosphoglyceride metabolism in human colon cancer.
Mol Cell Biochem
162:
97-103,
1996[ISI][Medline].
17.
Evelhoch, JL,
Gillies RJ,
Karczmar GS,
Koutcher JA,
Maxwell RJ,
Nalcioglu O,
Raghunand N,
Ronen SM,
Ross BD,
and
Swartz HM.
Applications of magnetic resonance in model systems: cancer therapeutics.
Neoplasia
2:
151-165,
2000.
18.
Freyer, JP.
Rates of oxygen consumption for proliferating and quiescent cells isolated from multicellular spheroids.
Adv Exp Med Biol
345:
335-342,
1994[Medline].
19.
Freyer, JP.
Mitochondrial function of proliferating and quiescent cells isolated from multicellular tumor spheroids.
J Cell Physiol
176:
138-149,
1998[ISI][Medline].
20.
Freyer, JP,
Fink NH,
Schor PL,
Coulter JP,
Neeman M,
and
Sillerud LO.
A system for viably maintaining a stirred suspension of multicellular spheroids during NMR spectroscopy.
NMR Biomed
3:
195-205,
1990[Medline].
21.
Freyer, JP,
Schor P,
Jarrett KA,
Neeman M,
and
Sillerud LO.
Cellular energetics measured by phosphorous nuclear magnetic resonance spectroscopy are not correlated with chronic nutrient deficiency in multicellular tumor spheroids.
Cancer Res
51:
3831-3837,
1991[Abstract].
22.
Freyer, JP,
and
Sutherland RM.
A reduction in the in situ rates of oxygen and glucose consumption of cells in EMT6/Ro spheroids during growth.
J Cell Physiol
124:
516-524,
1985[ISI][Medline].
23.
Freyer, JP,
and
Sutherland RM.
Regulation of growth saturation and development of necrosis in EMT6/Ro multicellular spheroids by the glucose and oxygen supply.
Cancer Res
46:
3504-3512,
1986[Abstract].
24.
Fu, KK,
Wendland MF,
Iyler SB,
Lam KN,
Engeseth H,
and
James TL.
Correlations between in vivo 31P NMR spectroscopy measurements, tumor size, hypoxic fraction and cell survival after radiotherapy.
Int J Radiat Oncol Biol Phys
18:
1341-1350,
1990[ISI][Medline].
25.
Gerweck, LE,
Koutcher JA,
Zaidi ST,
and
Seneviratne T.
Energy status in the murine FSaII and MCaIV tumors under aerobic and hypoxic conditions: an in-vivo and in-vitro analysis.
Int J Radiat Oncol Biol Phys
23:
557-561,
1992[ISI][Medline].
26.
Gillies, RJ,
Barry JA,
and
Ross BD.
In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells.
Magn Reson Med
32:
310-318,
1994[ISI][Medline].
27.
Gillies, RJ,
Bhujwalla ZM,
Evelhoch S,
Garwood M,
Neeman M,
Robinson SP,
Sotak CH,
and
VanderSanden B.
Applications of magnetic resonance in model systems: tumor biology and physiology.
Neoplasia
2:
139-151,
2000[ISI][Medline].
28.
Granada, F,
Iorio E,
Carpinelli G,
Giannini M,
and
Podo F.
Phosphocholine and phosphoethanolamine during chick embryo myogenesis: a 31P-NMR study.
Biochim Biophys Acta
1483:
334-342,
2000[ISI][Medline].
29.
Groebe, K,
and
Mueller-Klieser W.
On the relation between size of necrosis and diameter of tumor spheroids.
Int J Radiat Oncol Biol Phys
34:
395-401,
1996[ISI][Medline].
30.
Holm, DM,
and
Cram LS.
An improved flow microfluorometer for rapid measurement of cell fluorescence.
Exp Cell Res
80:
105-110,
1973[ISI][Medline].
31.
Jackel, MC,
Kopf-Maier P,
Baumgart F,
Ziessow D,
and
Tausch-Treml R.
Value of 31P NMR spectroscopy in predicting the response of a xenografted human hypopharynx carcinoma to irradiation.
J Cancer Res Clin Oncol
126:
325-331,
2000[ISI][Medline].
32.
Katz-Brull, R,
and
Degani H.
Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method.
Anticancer Res
16:
1375-1380,
1996[ISI][Medline].
33.
Kiss, Z,
Crilly KS,
and
Anderson WH.
Carcinogens stimulate phosphorylation of ethanolamine derived from increased hydrolysis of phosphatidylethanolamine in C3H/101/2 fibroblasts.
FEBS Lett
336:
115-118,
1993[ISI][Medline].
34.
Kroeger, M,
Walenta S,
Rofstad EK,
and
Mueller-Klieser W.
Growth rates or radiobiological hypoxia are not correlated with local metabolite content in human melanoma xenografts with similar vascular network.
Br J Cancer
72:
912-916,
1995[ISI][Medline].
35.
Kunz, LA,
and
Mueller-Klieser W.
Oncogene-associated growth behavior and oxygenation of multicellular spheroids from rat embryo fibroblasts.
Adv Exp Med Biol
345:
359-366,
1994[Medline].
36.
Kunz-Schughart, LA,
Groebe K,
and
Mueller-Klieser W.
Three-dimensional cell culture induces novel proliferative and metabolic alterations associated with oncogenic transformation.
Int J Cancer
66:
578-586,
1996[ISI][Medline].
37.
Kunz-Schughart, LA,
Habbersett RC,
and
Freyer JP.
Mitochondrial function in oncogene-transfected rat fibroblasts isolated from multicellular spheroids.
Am J Physiol Cell Physiol
273:
C1487-C1495,
1997
38.
Kunz-Schughart, LA,
Habbersett RC,
and
Freyer JP.
Impact of proliferative activity and tumorigenic conversion on mitochondrial function of fibroblasts in 2D and 3D culture.
Cell Biol Int
25:
919-930,
2001[ISI][Medline].
39.
Kunz-Schughart, LA,
Kreutz M,
and
Knuechel R.
Multicellular spheroids: a three-dimensional in vitro culture system to study tumor biology.
Int J Exp Pathol
79:
1-23,
1998[ISI][Medline].
40.
Kunz-Schughart, LA,
Simm A,
and
Mueller-Klieser W.
Oncogene-associated transformation of early passage rodent fibroblasts is accompanied by large morphologic and metabolic alterations.
Oncol Rep
2:
651-661,
1995[ISI].
41.
Leach, MO.
Introduction to in vivo MRS of cancer: new perspectives and open problems.
Anticancer Res
16:
1503-1514,
1996[ISI][Medline].
42.
Leach, MO,
Verrill M,
Glaholm J,
Smith TAD,
Collins DJ,
Payne GS,
Sharp JC,
Ronen SM,
McCready VR,
Powles TJ,
and
Smith IE.
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment.
NMR Biomed
11:
314-340,
1998[ISI][Medline].
43.
Lehnhardt, FG,
Rohn G,
Ernestus RI,
Grune M,
and
Hoehn M.
1H- and 31P-MR spectroscopy of primary and recurrent human brain tumors in vitro: malignancy-characteristic profiles of water soluble and lipophilic spectral components.
NMR Biomed
14:
307-317,
2001[ISI][Medline].
44.
Lyng, H,
Olsen DR,
Petersen SB,
and
Rofstad EK.
31P-NMR spectroscopy studies of phospholipid metabolism in human melanoma xenograft lines differing in rate of tumour cell proliferation.
NMR Biomed
8:
65-71,
1995[ISI][Medline].
45.
Mahmood, U,
Alfieri AA,
Ballon D,
Traganos F,
and
Koutcher JA.
In vitro and in vivo 31P nuclear magnetic resonance measurements of metabolic changes post radiation.
Cancer Res
55:
1248-1254,
1995[Abstract].
46.
Maier, M.
In vivo magnetic resonance spectroscopy: applications in psychiatry.
Br J Psychiatry
167:
299-306,
1995[Abstract].
47.
Malet-Martino, MC,
and
Martino R.
Magnetic resonance spectroscopy: a powerful tool for drug metabolism studies.
Biochimie
74:
785-800,
1992[ISI][Medline].
48.
McCoy, CL,
Parkins CS,
Chaplin DJ,
Griffith S,
Rodrigues LM,
and
Stubbs M.
The effect of blood flow modifications on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumors.
Br J Cancer
72:
905-911,
1995[ISI][Medline].
49.
McCully, K,
Shellock FG,
Bank WJ,
and
Posner JD.
The use of nuclear magnetic resonance to evaluate muscle injury.
Med Sci Sports Exerc
24:
537-542,
1992[ISI][Medline].
50.
McSheehy, PMJ,
Seymour MT,
Ojugo ASE,
Rodrigues LM,
Leach MO,
Judson IR,
and
Griffiths JR.
A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy.
Eur J Cancer
33:
2418-2427,
1997[ISI][Medline].
51.
Merchant, TE,
Alfieri AA,
Glonek T,
and
Koutcher JA.
Comparison of relative changes in phosphatic metabolites and phospholipids after irradiation.
Radiat Res
142:
29-38,
1995[ISI][Medline].
52.
Merchant, TE,
Diamantis PM,
Lauwers G,
Haida T,
Kasimos JN,
Guillem J,
Glonek T,
and
Minsky BD.
Characterization of malignant colon tumors with 31P nuclear magnetic resonance phospholipid and phosphatic metabolic profiles.
Cancer
76:
1715-1723,
1995[ISI][Medline].
53.
Mueller-Klieser, W.
Three-dimensional cell cultures: from molecular mechanisms to clinical applications.
Am J Physiol
43:
C1109-C1123,
1997.
54.
Negendank, W.
Studies of human tumors by MRS: a review.
NMR Biomed
5:
303-324,
1992[ISI][Medline].
55.
Negendank, W,
Li CW,
Shaller KP,
Murphy-Boesch J,
and
Brown TR.
Phospholipid metabolites in 1H-decoupled 31P MRS in vivo in human cancer: implications for experimental models and clinical studies.
Anticancer Res
16:
1539-1544,
1996[ISI][Medline].
56.
Newell, DR,
Maxwell RJ,
and
Golding BT.
In vivo and ex vivo magnetic resonance spectroscopy as applied to pharmacokinetic studies with anticancer agents: a review.
NMR Biomed
5:
273-278,
1992[ISI][Medline].
57.
Ng, TC,
Grundfest S,
Vijayakuma S,
Baldwin NJ,
Majors AW,
Karalis I,
Meaney TF,
Shin KH,
Thomas FJ,
and
Tubbs R.
Therapeutical response of breast carcinoma monitored by 31P MRS in situ.
Magn Reson Med
10:
125-134,
1989[ISI][Medline].
58.
Nielsen, FU,
Daugaard P,
Bentzen L,
Stodkilde-Jorgensen H,
Overgaard J,
Horsman MR,
and
Maxwell RJ.
Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy.
Cancer Res
61:
5318-5325,
2001
59.
Nordsmark, M,
Grau C,
Horsman MR,
Jorgensen HS,
and
Overgaard J.
Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model.
Acta Oncol
34:
329-334,
1995[ISI][Medline].
60.
Nordsmark, M,
Keller J,
Nielsen OS,
Lundorf E,
and
Overgaard J.
Tumor oxygenation assessed by polarographic needle electrodes and bioenergetic status measured by 31P magnetic resonance spectroscopy in human soft tissue tumors.
Acta Oncol
36:
565-571,
1997[ISI][Medline].
61.
Passe, TJ,
Charles HC,
Rajagopalan P,
and
Krishnan KR.
Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications.
Prog Neuropsychopharmacol Biol Psychiatry
19:
541-563,
1995[ISI][Medline].
62.
Podo, F.
Tumor phospholipid metabolism.
NMR Biomed
12:
413-439,
1999[ISI][Medline].
63.
Rasmussen, J,
Hansen LL,
Friche E,
and
Jaroszewski JW.
31P and 13C NMR spectroscopic study of wild-type and multidrug-resistant Ehrlich ascites tumor cells.
Oncol Res
5:
119-126,
1993[ISI][Medline].
64.
Romero, FJ,
Zukowski D,
and
Mueller-Klieser W.
Glutathione content of V79 cells in two- or three-dimensional culture.
Am J Physiol
41:
C1507-C1512,
1997[ISI].
65.
Ronen, SM,
and
Leach MO.
Imaging biochemistry: applications to breast cancer.
Breast Cancer Res
3:
36-40,
2001[ISI][Medline].
66.
Ronen, SM,
Rushkin E,
and
Degani H.
Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake.
Biochim Biophys Acta
1095:
5-16,
1991[ISI][Medline].
67.
Rudin, M,
Beckmann N,
Mir A,
and
Sauter A.
In-vivo magnetic-resonance-imaging and spectroscopy in pharmacological research: assessment of morphological, physiological and metabolic effects of drugs.
Eur J Pharm Sci
3:
255-264,
1995[ISI].
68.
Ruiz-Cabello, J,
and
Cohen JS.
Phospholipid metabolites as indicators of cancer cell function.
NMR Biomed
5:
226-233,
1992[ISI][Medline].
69.
Sharma, RK,
and
Jain V.
Radiotherapeutic response of Ehrlich ascites tumor cells perfused in agarose gel threads and implanted in mice: a 31P MR spectroscopy study.
Strahlenther Onkol
177:
212-219,
2001[ISI][Medline].
70.
Sijens, PE.
Phosphorus NMR spectroscopy in the treatment of human extremity sarcomas.
NMR Biomed
11:
341-353,
1998[ISI][Medline].
71.
Singer, S,
Souza K,
and
Thilly WG.
Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study.
Cancer Res
55:
5140-5145,
1995[Abstract].
72.
Smith, TAD,
Eccles S,
Ormerod MG,
Tombs AJ,
Titley JC,
and
Leach MO.
The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rates.
Br J Cancer
64:
821-826,
1991[ISI][Medline].
73.
Smith, TAD,
Glaholm J,
Leach MO,
Machin L,
and
McCready VR.
The effect of intra-tumour heterogeneity on the distribution of phosphorus-containing metabolites within human breast tumours: an in vitro study using 31P-NMR spectroscopy.
NMR Biomed
4:
262-267,
1991[ISI][Medline].
74.
Steen, RG.
Characterization of tumor hypoxia by 31P MR spectroscopy.
AJR Am J Roentgenol
157:
243-248,
1991[Abstract].
75.
Street, JC,
and
Koutcher JA.
Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids.
Lipids
32:
45-49,
1997[ISI][Medline].
76.
Street, JC,
Szwergold BS,
Matei C,
Kappler F,
Mahmood U,
Brown TR,
and
Koutcher JA.
Study of the metabolism of choline and phosphatidylcholine in tumors in vivo using phosphonium-chloride.
Magn Reson Med
38:
769-775,
1997[ISI][Medline].
77.
Szwergold, BS,
Kappler F,
Moldes M,
Shaller C,
and
Brown TR.
Characterization of a phosphonium analog of choline as a probe in 31P NMR studies of phospholipid metabolism.
NMR Biomed
7:
121-127,
1994[ISI][Medline].
78.
Teutsch, HF,
Goellner A,
and
Mueller-Klieser W.
Glucose level and succinate and lactate dehydrogenase activity in EMT6/Ro tumor spheroids.
Eur J Cell Biol
66:
302-307,
1995[ISI][Medline].
79.
Thomas, CP,
Dixon RM,
Tiam M,
Butler SA,
Counsell CJR,
Bradley JK,
Adams GE,
and
Radda GK.
Phosphorus metabolism during growth of lymphoma in mouse liver: a comparison of 31P magnetic resonance spectroscopy in vivo and in vitro.
Br J Cancer
69:
633-640,
1994[ISI][Medline].
80.
Ting, YL,
Sherr D,
and
Degani H.
Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells.
Anticancer Res
16:
1381-1388,
1996[ISI][Medline].
81.
Tozer, GM,
and
Griffith S.
The contribution made by cell death and oxygenation to 31P MRS observations of tumor energy metabolism.
NMR Biomed
5:
279-289,
1992[ISI][Medline].
82.
Vance, DE,
Houweling M,
Lee M,
and
Cui Z.
Phosphatidylethanolamine methylation and hepatoma cell growth.
Anticancer Res
16:
1413-1416,
1996[ISI][Medline].
83.
Van den Bosch, H.
Phosphoglyceride metabolism.
Annu Rev Biochem
43:
243-277,
1974[ISI][Medline].
84.
Vandent-Hillart, G,
and
VanWaarde A.
Nuclear magnetic resonance spectroscopy of living systems: applications in comparative physiology.
Physiol Rev
76:
799-837,
1996
85.
Vaupel, P,
Schaefer C,
and
Okunieff P.
Intracellular acidosis in murine fibrosarcomas coincides with ATP depletion, hypoxia, and high levels of lactate and total Pi.
NMR Biomed
7:
128-136,
1994[ISI][Medline].
86.
Walenta, S,
Doetsch J,
Mueller-Klieser W,
and
Kunz-Schughart LA.
Metabolic imaging in multicellular spheroids of oncogene-transfected fibroblasts.
J Histochem Cytochem
48:
509-522,
2000
87.
Ziegler, A,
von Kienlin M,
Decorps M,
and
Remy C.
High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging.
Cancer Res
61:
5595-5600,
2001
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |